K&L Gates Advises Axonics on $150 Million Follow-On Public Offering

22 May 2020

Orange County – Global law firm K&L Gates LLP has advised Axonics Modulation Technologies (NASDAQ: AXNX) on its public offering of 4 million shares of common stock, which raised $150 million in gross proceeds before underwriting discounts, commissions, and offering expenses.

Axonics is a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (SNM) devices for the treatment of bladder and bowel dysfunction, with net proceeds from this latest offering intended to support the technological enhancement and commercialization of Axonics’ r-SNM System in North America and Europe, SNM-related research and development activities, and general corporate purposes. This is the third public offering on which K&L Gates represented Axonics, including its October 2018 initial public offering and its November 2019 follow-on offering.

The K&L Gates team that advised Axonics on this latest offering was led by Orange County office managing partner Michael Hedge. Other key team members from K&L Gates included partners Louis Cullman, Jason Dreibelbis, and Michael Hinckle, and associates Jacqulyn Lewis and Jacob Reichman.

Please enable JavaScript, then refresh this page. JavaScript is required on this site.